{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T19:53:46Z","timestamp":1785268426868,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This retrospective natural history study used real-world data to describe baseline demographics, comorbidities, clinical characteristics, and treatments, and assess incidence rates (IRs) of extra-muscular outcomes in patients with incident dermatomyositis (DM), polymyositis (PM), juvenile DM (JDM), and juvenile PM (JPM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>De-identified clinical data were collected from the US Optum\u00ae electronic health records with supplemental claims (01 January 2016 to 31 March 2021). Total 9,009 patients were included (DM: 4,275; PM: 4,559; JDM: 128; JPM: 47). IRs of 13 outcomes were estimated in patients and an equal number of sex- and age-matched controls (MCs) without DM\/PM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Mean age at index was 54.5 (DM), 57.3 (PM), 14.3 (JDM), and 15.1\u00a0years (JPM). Most common comorbidities were hypertension in DM (50.3%) and PM (63.9%) cohorts, dysphagia in JDM (15.6%) and liver disease in JPM (23.4%) cohorts. Most common clinical characteristics were Raynaud\u2019s phenomenon in DM (8.6%), PM (7.9%), and JDM (11.7%) cohorts, and arthritis in JPM (10.6%) cohort. Systemic steroids were the most frequent medication (DM: 70.3%; PM: 68.3%; JDM: 73.4%; JPM: 59.6%). IRs (per 100 person years) of outcomes in all cohorts were higher in patients versus their MCs. In DM and PM cohorts, highest IRs were observed for gastroesophageal reflux disease (DM:10.3; PM:12.8). In JDM cohort, dysphagia (4.3) had highest IR. In JPM cohort, cardiac dysrhythmia (3.5) had highest IR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study addresses existing gaps in understanding the descriptive epidemiology of DM and PM in the US, particularly the IRs of extra-muscular disease manifestations and malignancy events.<\/jats:p>\n                    <jats:table-wrap>\n                      <jats:table>\n                        <jats:tbody>\n                          <jats:tr>\n                            <jats:td colspan=\"2\">\n                              <jats:bold>Key Points<\/jats:bold>\n                              \u2022\n                              <jats:italic>This study provides a comprehensive description of demographic and disease characteristics in a large and nationally representative sample of adult and juvenile patients with incident DM and PM in the US.<\/jats:italic>\n                              \u2022\n                              <jats:italic>The results cover wide arrays of demographics, comorbidities, clinical characteristics, treatment exposures, and extra-muscular disease manifestations and malignancies in patients with incident DM and PM.<\/jats:italic>\n                              \u2022\n                              <jats:italic>The results frequently align with findings from other, smaller studies in patients with myositis.<\/jats:italic>\n                            <\/jats:td>\n                          <\/jats:tr>\n                        <\/jats:tbody>\n                      <\/jats:table>\n                    <\/jats:table-wrap>\n                  <\/jats:sec>","DOI":"10.1007\/s10067-025-07614-6","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T05:23:28Z","timestamp":1756358608000},"page":"4237-4247","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A retrospective natural history study in adult and juvenile patients with incident dermatomyositis and polymyositis using real world data"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7329-1254","authenticated-orcid":false,"given":"David M.","family":"Barnes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia E.","family":"Borlenghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen E.","family":"Schachterle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Sile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"issue":"11","key":"7614_CR1","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.18553\/jmcp.2020.26.11.1424","volume":"26","author":"L Christopher-Stine","year":"2020","unstructured":"Christopher-Stine L, Wan GJ, Kelly W, McGowan M, Bostic R, Reed ML (2020) Patient-reported dermatomyositis and polymyositis flare symptoms are associated with disability, productivity loss, and health care resource use. J Manag Care Spec Pharm 26(11):1424\u20131433. https:\/\/doi.org\/10.18553\/jmcp.2020.26.11.1424","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"7614_CR2","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/joim.13309","volume":"290","author":"A Yafasova","year":"2021","unstructured":"Yafasova A, Diederichsen LP, Schou M, Sun G, Torp-Pedersen C, Gislason GH et al (2021) Increased long-term risk of heart failure and other adverse cardiac outcomes in dermatomyositis and polymyositis: Insights from a nationwide cohort. J Intern Med 290(3):704\u2013714. https:\/\/doi.org\/10.1111\/joim.13309","journal-title":"J Intern Med"},{"key":"7614_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/1471-2474-13-103","volume":"13","author":"KE Smoyer-Tomic","year":"2012","unstructured":"Smoyer-Tomic KE, Amato AA, Fernandes AW (2012) Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, Medicare supplemental insured, and Medicaid enrolled populations: an administrative claims analysis. BMC Musculoskelet Disord 13:103. https:\/\/doi.org\/10.1186\/1471-2474-13-103","journal-title":"BMC Musculoskelet Disord"},{"issue":"3","key":"7614_CR4","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/j.1756-185X.2011.01669.x","volume":"16","author":"JA Tan","year":"2013","unstructured":"Tan JA, Roberts-Thomson PJ, Blumbergs P, Hakendorf P, Cox SR, Limaye V (2013) Incidence and prevalence of idiopathic inflammatory myopathies in South Australia: a 30-year epidemiologic study of histology-proven cases. Int J Rheum Dis 16(3):331\u2013338. https:\/\/doi.org\/10.1111\/j.1756-185X.2011.01669.x","journal-title":"Int J Rheum Dis"},{"issue":"8","key":"7614_CR5","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.3346\/jkms.2019.34.e55","volume":"34","author":"S-K Cho","year":"2019","unstructured":"Cho S-K, Kim H, Myung J, Nam E, Jung S-Y, Jang EJ et al (2019) Incidence and prevalence of idiopathic inflammatory myopathies in Korea: a nationwide population-based study. J Korean Med Sci 34(8):e55. https:\/\/doi.org\/10.3346\/jkms.2019.34.e55","journal-title":"J Korean Med Sci"},{"issue":"5","key":"7614_CR6","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1002\/mus.23302","volume":"45","author":"DE Furst","year":"2012","unstructured":"Furst DE, Amato AA, Iorga \u015eR, Gajria K, Fernandes AW (2012) Epidemiology of adult idiopathic inflammatory myopathies in a US managed care plan. Muscle Nerve 45(5):676\u2013683. https:\/\/doi.org\/10.1002\/mus.23302","journal-title":"Muscle Nerve"},{"key":"7614_CR7","doi-asserted-by":"publisher","unstructured":"Engel TN, Roberts CM, Tartar DM (2021) Characteristics of patients with dermatomyositis from 2011\u20132021 at a tertiary care center. Dermatol Online J 27(11). https:\/\/doi.org\/10.5070\/D3271156094","DOI":"10.5070\/D3271156094"},{"issue":"1","key":"7614_CR8","doi-asserted-by":"publisher","first-page":"17172","DOI":"10.1038\/s41598-023-44092-9","volume":"13","author":"Q Hu","year":"2023","unstructured":"Hu Q, Huang K-C, Goh CH, Tsuchiya Y, Liu Y, Qiu H (2023) Characteristics and risk of interstitial lung disease in dermatomyositis and polymyositis: a retrospective cohort study in Japan. Sci Rep 13(1):17172. https:\/\/doi.org\/10.1038\/s41598-023-44092-9","journal-title":"Sci Rep"},{"issue":"2","key":"7614_CR9","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/acr.24786","volume":"75","author":"VL Kronzer","year":"2023","unstructured":"Kronzer VL, Kimbrough BA, Crowson CS, Davis JM III, Holmqvist M, Ernste FC (2023) Incidence, prevalence, and mortality of dermatomyositis: a population-based cohort study. Arthritis Care Res (Hoboken) 75(2):348\u2013355. https:\/\/doi.org\/10.1002\/acr.24786","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"7614_CR10","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1111\/j.1365-2133.2011.10595.x","volume":"165","author":"CF Kuo","year":"2011","unstructured":"Kuo CF, See LC, Yu KH, Chou IJ, Chang HC, Chiou MJ et al (2011) Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: a nationwide population study. Br J Dermatol 165(6):1273\u20131279. https:\/\/doi.org\/10.1111\/j.1365-2133.2011.10595.x","journal-title":"Br J Dermatol"},{"issue":"3","key":"7614_CR11","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1002\/art.11122","volume":"49","author":"EP Mendez","year":"2003","unstructured":"Mendez EP, Lipton R, Ramsey-Goldman R, Roettcher P, Bowyer S, Dyer A et al (2003) US incidence of juvenile dermatomyositis, 1995\u20131998: results from the national institute of arthritis and musculoskeletal and skin diseases registry. Arthritis Rheum 49(3):300\u2013305. https:\/\/doi.org\/10.1002\/art.11122","journal-title":"Arthritis Rheum"},{"issue":"1","key":"7614_CR12","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s42466-022-00226-4","volume":"4","author":"M Pawlitzki","year":"2022","unstructured":"Pawlitzki M, Acar L, Masanneck L, Willison A, Regner-Nelke L, Nelke C et al (2022) Myositis in Germany: epidemiological insights over 15 years from 2005 to 2019. Neurol Res Pract 4(1):62. https:\/\/doi.org\/10.1186\/s42466-022-00226-4","journal-title":"Neurol Res Pract"},{"issue":"5","key":"7614_CR13","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1093\/rheumatology\/kew503","volume":"56","author":"J Svensson","year":"2017","unstructured":"Svensson J, Arkema EV, Lundberg IE, Holmqvist M (2017) Incidence and prevalence of idiopathic inflammatory myopathies in Sweden: a nationwide population-based study. Rheumatology (Oxford) 56(5):802\u2013810. https:\/\/doi.org\/10.1093\/rheumatology\/kew503","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"7614_CR14","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1016\/S2665-9913(23)00322-3","volume":"6","author":"CM Connolly","year":"2024","unstructured":"Connolly CM, Gupta L, Fujimoto M, Machado PM, Paik JJ (2024) Idiopathic inflammatory myopathies: current insights and future frontiers. Lancet Rheumatol 6(2):e115\u2013e127. https:\/\/doi.org\/10.1016\/S2665-9913(23)00322-3","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"7614_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13075-023-03232-2","volume":"26","author":"R Aggarwal","year":"2024","unstructured":"Aggarwal R, Schessl J, Charles-Schoeman C, Bata-Cs\u00f6rg\u0151 Z, Dimachkie MM, Griger Z et al (2024) Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study. Arthritis Res Ther 26(1):27. https:\/\/doi.org\/10.1186\/s13075-023-03232-2","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"7614_CR16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s40674-022-00193-6","volume":"8","author":"MP Chung","year":"2022","unstructured":"Chung MP, Paik JJ (2022) Past, present, and future in dermatomyositis therapeutics. Curr Treatm Opt Rheumatol 8(4):71\u201390. https:\/\/doi.org\/10.1007\/s40674-022-00193-6","journal-title":"Curr Treatm Opt Rheumatol"},{"issue":"5","key":"7614_CR17","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nrrheum.2018.42","volume":"14","author":"CV Oddis","year":"2018","unstructured":"Oddis CV, Aggarwal R (2018) Treatment in myositis. Nat Rev Rheumatol 14(5):279\u2013289. https:\/\/doi.org\/10.1038\/nrrheum.2018.42","journal-title":"Nat Rev Rheumatol"},{"key":"7614_CR18","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2147\/ITT.S381472","volume":"13","author":"L Cassard","year":"2024","unstructured":"Cassard L, Seraly N, Riegert M, Patel A, Fernandez AP (2024) Dermatomyositis: practical guidance and unmet needs. Immunotargets Ther 13:151\u2013172. https:\/\/doi.org\/10.2147\/ITT.S381472","journal-title":"Immunotargets Ther"},{"issue":"6","key":"7614_CR19","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1093\/rheumatology\/keaa661","volume":"60","author":"KM D\u2019Silva","year":"2021","unstructured":"D\u2019Silva KM, Li L, Lu N, Ogdie A, Avina-Zubieta JA, Choi HK (2021) Persistent premature mortality gap in dermatomyositis and polymyositis: a United Kingdom general population-based cohort study. Rheumatology (Oxford) 60(6):2653\u20132660. https:\/\/doi.org\/10.1093\/rheumatology\/keaa661","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"7614_CR20","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.3390\/diagnostics12051200","volume":"12","author":"A Matas-Garcia","year":"2022","unstructured":"Matas-Garcia A, Milisenda JC, Espinosa G, Cuatrecasas M, Selva-O\u2019Callaghan A, Grau JM et al (2022) Gastrointestinal involvement in dermatomyositis. Diagnostics (Basel) 12(5):1200. https:\/\/doi.org\/10.3390\/diagnostics12051200","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"7614_CR21","doi-asserted-by":"publisher","first-page":"16444","DOI":"10.1038\/s41598-023-43880-7","volume":"13","author":"M Osman","year":"2023","unstructured":"Osman M, Martins KJ, Wong KO, Vu K, Guigue A, Cohen Tervaert JW et al (2023) Incidence and prevalence, and medication use among adults living with dermatomyositis: an Alberta. Canada population-based cohort study Sci Rep 13(1):16444. https:\/\/doi.org\/10.1038\/s41598-023-43880-7","journal-title":"Canada population-based cohort study Sci Rep"},{"key":"7614_CR22","unstructured":"Optum market clarity data. market clarity: Linked EHR and Claims Data. https:\/\/www.optum.com\/business\/life-sciences\/real-world-data\/market-clarity-data.html. Accessed Sep 2024"},{"issue":"1","key":"7614_CR23","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","volume":"7","author":"IE Lundberg","year":"2021","unstructured":"Lundberg IE, Fujimoto M, Vencovsky J, Aggarwal R, Holmqvist M, Christopher-Stine L et al (2021) Idiopathic inflammatory myopathies. Nat Rev Dis Primers 7(1):86. https:\/\/doi.org\/10.1038\/s41572-021-00321-x","journal-title":"Nat Rev Dis Primers"},{"key":"7614_CR24","unstructured":"ICD Codes. ICD Codes. https:\/\/icd.codes\/. Accessed Sep 2024"},{"key":"7614_CR25","unstructured":"Team RC. A language and environment for statistical computing_. R Foundation for Statistical Computing, Vienna, Austria. Accessed Sep 2024"},{"issue":"1","key":"7614_CR26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/MD.0b013e31827f264d","volume":"92","author":"M Shah","year":"2013","unstructured":"Shah M, Mamyrova G, Targoff IN, Huber AM, Malley JD, Rice MM et al (2013) The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 92(1):25\u201341. https:\/\/doi.org\/10.1097\/MD.0b013e31827f264d","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"7614_CR27","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1007\/s10067-019-04910-w","volume":"39","author":"X Yang","year":"2020","unstructured":"Yang X, Hao Y, Zhang X, Geng Y, Ji L, Li G et al (2020) Mortality of Chinese patients with polymyositis and dermatomyositis. Clin Rheumatol 39(5):1569\u20131579. https:\/\/doi.org\/10.1007\/s10067-019-04910-w","journal-title":"Clin Rheumatol"},{"issue":"6","key":"7614_CR28","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.reuma.2016.07.010","volume":"13","author":"L Nu\u00f1o","year":"2017","unstructured":"Nu\u00f1o L, Joven B, Carreira P, Maldonado V, Larena C, Llorente I et al (2017) Multicenter registry on inflammatory myositis from the Rheumatology Society in Madrid, Spain: descriptive analysis. Reumatol Clin 13(6):331\u2013337. https:\/\/doi.org\/10.1016\/j.reuma.2016.07.010","journal-title":"Reumatol Clin"},{"issue":"2","key":"7614_CR29","first-page":"188","volume":"32","author":"A Taborda","year":"2014","unstructured":"Taborda A, Azevedo P, Isenberg D (2014) Retrospective analysis of the outcome of patients with idiopathic inflammatory myopathy: a long-term follow-up study. Clin Exp Rheumatol 32(2):188\u2013193","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"7614_CR30","first-page":"117","volume":"29","author":"D Guseinova","year":"2011","unstructured":"Guseinova D, Consolaro A, Trail L, Ferrari C, Pistorio A, Ruperto N et al (2011) Comparison of clinical features and drug therapies among European and Latin American patients with juvenile dermatomyositis. Clin Exp Rheumatol 29(1):117\u2013124","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"7614_CR31","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.semarthrit.2020.07.011","volume":"50","author":"K-H Ng","year":"2020","unstructured":"Ng K-H, Chen D-Y, Lin C-H, Chao W-C, Chen Y-M, Chen Y-H et al (2020) Risk of interstitial lung disease in patients with newly diagnosed systemic autoimmune rheumatic disease: a nationwide, population-based cohort study. Semin Arthritis Rheum 50(5):840\u2013845. https:\/\/doi.org\/10.1016\/j.semarthrit.2020.07.011","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"7614_CR32","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s10741-019-09909-8","volume":"26","author":"AH Opinc","year":"2021","unstructured":"Opinc AH, Makowski MA, \u0141ukasik ZM, Makowska JS (2021) Cardiovascular complications in patients with idiopathic inflammatory myopathies: does heart matter in idiopathic inflammatory myopathies? Heart Fail Rev 26(1):111\u2013125. https:\/\/doi.org\/10.1007\/s10741-019-09909-8","journal-title":"Heart Fail Rev"},{"issue":"1","key":"7614_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.rdc.2013.10.002","volume":"40","author":"H Van Gelder","year":"2014","unstructured":"Van Gelder H, Charles-Schoeman C (2014) The heart in inflammatory myopathies. Rheum Dis Clin North Am 40(1):1\u201310. https:\/\/doi.org\/10.1016\/j.rdc.2013.10.002","journal-title":"Rheum Dis Clin North Am"},{"issue":"7","key":"7614_CR34","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/acr.22772","volume":"68","author":"L Diederichsen","year":"2016","unstructured":"Diederichsen L, Simonsen J, Diederichsen A, Hvidsten S, Hougaard M, Junker P et al (2016) Cardiac abnormalities in adult patients with polymyositis or dermatomyositis as assessed by noninvasive modalities. Arthritis Care Res (Hoboken) 68(7):1012\u20131020. https:\/\/doi.org\/10.1002\/acr.22772","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"7614_CR35","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3899\/jrheum.130346","volume":"41","author":"H Wang","year":"2014","unstructured":"Wang H, Liu H-X, Wang Y-L, Yu X-Q, Chen X-X, Cai L (2014) Left ventricular diastolic dysfunction in patients with dermatomyositis without clinically evident cardiovascular disease. J Rheumatol 41(3):495\u2013500. https:\/\/doi.org\/10.3899\/jrheum.130346","journal-title":"J Rheumatol"},{"issue":"1","key":"7614_CR36","doi-asserted-by":"publisher","first-page":"R7","DOI":"10.1186\/ar4135","volume":"15","author":"E Linos","year":"2013","unstructured":"Linos E, Fiorentino D, Lingala B, Krishnan E, Chung L (2013) Atherosclerotic cardiovascular disease and dermatomyositis: an analysis of the Nationwide Inpatient Sample survey. Arthritis Res Ther 15(1):R7. https:\/\/doi.org\/10.1186\/ar4135","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"7614_CR37","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.3899\/jrheum.090061","volume":"36","author":"A Tisseverasinghe","year":"2009","unstructured":"Tisseverasinghe A, Bernatsky S, Pineau CA (2009) Arterial events in persons with dermatomyositis and polymyositis. J Rheumatol 36(9):1943\u20131946. https:\/\/doi.org\/10.3899\/jrheum.090061","journal-title":"J Rheumatol"},{"issue":"5","key":"7614_CR38","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1136\/ard.2010.137968","volume":"70","author":"T Schwartz","year":"2011","unstructured":"Schwartz T, Sanner H, Husebye T, Flat\u00f8 B, Sjaastad I (2011) Cardiac dysfunction in juvenile dermatomyositis: a case-control study. Ann Rheum Dis 70(5):766\u2013771. https:\/\/doi.org\/10.1136\/ard.2010.137968","journal-title":"Ann Rheum Dis"},{"key":"7614_CR39","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s00296-017-3799-x","volume":"37","author":"L Nu\u00f1o-Nu\u00f1o","year":"2017","unstructured":"Nu\u00f1o-Nu\u00f1o L, Joven BE, Carreira PE, Maldonado-Romero V, Larena-Grijalba C, Cubas IL et al (2017) Mortality and prognostic factors in idiopathic inflammatory myositis: a retrospective analysis of a large multicenter cohort of Spain. Rheumatol Int 37:1853\u20131861. https:\/\/doi.org\/10.1007\/s00296-017-3799-x","journal-title":"Rheumatol Int"}],"updated-by":[{"DOI":"10.1007\/s10067-025-07800-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000}}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07614-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07614-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07614-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T12:03:02Z","timestamp":1763640182000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07614-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["7614"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07614-6","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]},"assertion":[{"value":"3 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2025","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article was originally published under the subscription model but it is now published under an Open Access license.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10067-025-07800-6","URL":"https:\/\/doi.org\/10.1007\/s10067-025-07800-6","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"David M. Barnes, Daniela Graham, and Stephen E. Schachterle are employees of Pfizer and hold Pfizer stocks. Cecilia E. Borlenghi and Helen Sile are stockholders and former employees of Pfizer. Thomas Edwards has no conflicts of interest or financial disclosures to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}